Mesentech

Mesentech has developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue. The advantage of our technology is that exposure to the active pharmaceutical occurs only in the targeted tissues, thereby eliminating toxicity to unrelated organs.

Our first product harnesses tissue-targeting technology to deliver prostaglandin, a potent hormone that triggers the body's own regenerative process, to renew and repair bone. It's safety profile would support its use not only in osteoporosis but also in certain pediatric osteoporosis diseases.

Learn more

Rosy Hu (Morningside) joins Mesentech’s board of directors

–

06.30.22

Ruoxi (Rosy) Hu Rosy is a member of the investment team at Morningside. Previously, she was on the investment team at Mass General Brigham Ventures where she focused on company creation and led early-stage seed investments. Rosy was trained as a molecular biologist. She received her PhD from Harvard University and undergraduate degree from Queen’s University in Canada.

Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions

–

03.21.21

Abstract: A series of bone-targeting EP4 receptor agonist conjugate prodrugs were prepared wherein a potent EP4 receptor agonist was bound to a biologically inactive, bisphosphonate-based bone-targeting moiety.